8-K: Glaukos Reports Record Q4 and Full Year 2024 Financial Results, Introduces Optimistic 2025 Revenue Guidance

Glaukos Corporation announces strong financial results for Q4 and full year 2024, driven by growth in glaucoma and corneal health franchises, and introduces 2025 net sales guidance of $475 million to $485 million.

Summary

• Glaukos Corporation reported record net sales of $105.5 million in Q4 2024, a 28% increase year-over-year.
• Glaucoma net sales reached a record $84.1 million in Q4 2024, up 39% year-over-year.
• The gross margin for Q4 2024 was approximately 73%, with a non-GAAP gross margin of approximately 82%.
• For the full year 2024, net sales totaled $383.5 million, a 22% increase compared to the previous year.
• The company introduced 2025 net sales guidance of $475 million to $485 million.
• The company ended the fourth quarter of 2024 with approximately $324 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with record sales and revenue growth, but also acknowledges some challenges and potential headwinds. The sentiment is cautiously optimistic.

Positives

• Glaukos reported record net sales for both Q4 2024 and the full year 2024.
• The company experienced significant growth in glaucoma net sales, particularly in the U.S. due to iDose TR.
• Glaukos has a strong cash position with approximately $324 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.
• The company is advancing its pipeline of novel dropless platform technologies.
• The company issued a notice of redemption for the remaining $57.5 million in principal amount outstanding of their convertible senior notes due 2027.
• The company entered into unwind agreements with certain financial institutions relating to a portion of the capped call transactions that they previously entered into in connection with the issuance of their 2.75% Convertible Senior Notes due 2027 in an aggregate principal amount of $287.5 million, generating cash proceeds of approximately $53.2 million.

Negatives

• The gross margin decreased from approximately 77% in Q4 2023 to approximately 73% in Q4 2024.
• Corneal Health net revenues declined by 2% in Q4 2024 compared to Q4 2023.
• The company reported a net loss of $33.6 million in Q4 2024.
• The company reported a net loss of $146.4 million for the full year 2024.
• The company expects potential headwinds within the U.S. Glaucoma stent business associated with the final MIGS LCDs in 5 of the 7 MACs.
• The company expects potential headwinds within the U.S. Corneal Health franchise associated with their entry as a company into the MDRP.
• The company expects the sunsetting of the year-over-year growth tailwind associated with the new French Health Authority rebate agreement.
• The company expects combo-cataract MIGS competition globally.

Risks

• The company's ability to successfully commercialize iDose TR therapy is subject to risks and uncertainties.
• General macroeconomic conditions, including foreign currency fluctuations and future health crises, could impact the business.
• The company depends on a limited number of third-party suppliers, some of which are single-source, for components of its products.
• Securing or maintaining adequate coverage or reimbursement by third-party payors for procedures using the company's products is critical.
• The company's compliance with federal, state, and foreign laws and regulations is essential for the approval and sale of its products.
• The lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes pose risks.
• The company faces the risk of recalls or serious safety issues with its products and the uncertainty of patient outcomes.
• The company's ability to protect its information systems against cyber threats and cybersecurity incidents is crucial.
• The company's ability to protect its intellectual property against third parties and competitors is essential.
• The company's ability to service its indebtedness is subject to risks.

Future Outlook

Glaukos expects full-year 2025 global consolidated net sales of $475 $485 million, taking into consideration potential contributions from iDose TR and iStent infinite, as well as potential headwinds from various factors including MIGS LCDs, MDRP, and foreign currency exchange rates.

Management Comments

• Our record fourth quarter results cap off a successful year of global execution of our key commercial and development plans, leaving us well positioned to continue to drive the strong momentum in our business this year and beyond, said Thomas Burns, Glaukos chairman and chief executive officer.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Industry Context

Glaukos is a key player in the ophthalmic pharmaceutical and medical technology industry, particularly in the glaucoma and corneal health segments. The company's focus on micro-invasive glaucoma surgery (MIGS) and sustained-release drug delivery systems positions it to compete with established pharmaceutical and medical device companies. The launch of iDose TR and the development of other novel therapies could disrupt the traditional treatment paradigms for chronic eye diseases.

Comparison to Industry Standards

• Glaukos's growth in glaucoma net sales, particularly in the U.S. with iDose TR, positions it favorably against competitors like Alcon and Allergan in the glaucoma treatment market.
• The company's focus on MIGS and sustained-release drug delivery systems aligns with the industry trend towards less invasive and more patient-friendly treatment options.
• The 2025 revenue guidance of $475 million to $485 million reflects the company's confidence in its product pipeline and commercial execution, suggesting a competitive stance against other players in the ophthalmic market.

Stakeholder Impact

• Shareholders can expect continued growth and potential value creation from the company's innovative products and expanding market presence.
• Employees may benefit from the company's growth and expansion plans, including the new research, development, and manufacturing facility in Huntsville, Alabama.
• Customers (patients) can expect improved treatment options and outcomes from the company's novel therapies for glaucoma, corneal disorders, and retinal diseases.
• Suppliers may benefit from increased demand for components of the company's products.
• Creditors may have increased confidence in the company's ability to service its debt due to its strong financial position.

Next Steps

• Advance commercial launch activities in the U.S. for iDose TR.
• Expand access for and utilization of iStent infinite.
• Commence initial preparatory planning for potential Epioxa FDA approval and commercial launch.
• Advance dialogue with the FDA regarding the re-administration of iDose TR.
• Advance various Phase 4 studies for iDose TR.
• Advance patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients.
• Advance patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401).
• Advance Phase 2 clinical program for third-generation iLink therapy.
• Prepare to commence Phase 2 clinical trial for iLution Blepharitis by end of 2025.
• Prepare to commence U.S. Investigation Device Exemption (IDE) study for PRESERFLO MicroShunt in 1H 2025.

Key Dates